US20160271139A1 - Method for non-toxic treatment for drug withdrawal - Google Patents
Method for non-toxic treatment for drug withdrawal Download PDFInfo
- Publication number
- US20160271139A1 US20160271139A1 US14/346,655 US201414346655A US2016271139A1 US 20160271139 A1 US20160271139 A1 US 20160271139A1 US 201414346655 A US201414346655 A US 201414346655A US 2016271139 A1 US2016271139 A1 US 2016271139A1
- Authority
- US
- United States
- Prior art keywords
- noribogaine
- patient
- hours
- dose
- intervals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 56
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 title claims description 33
- 238000011282 treatment Methods 0.000 title description 25
- 231100000252 nontoxic Toxicity 0.000 title 1
- 230000003000 nontoxic effect Effects 0.000 title 1
- RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 claims abstract description 211
- RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 claims abstract description 194
- 210000002966 serum Anatomy 0.000 claims description 45
- 206010012335 Dependence Diseases 0.000 claims description 35
- 239000000126 substance Substances 0.000 claims description 30
- 206010013663 drug dependence Diseases 0.000 abstract description 7
- 208000011117 substance-related disease Diseases 0.000 abstract description 5
- 230000002939 deleterious effect Effects 0.000 abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 229930182480 glucuronide Natural products 0.000 description 19
- -1 noribogaine glucuronide Chemical class 0.000 description 17
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 241000700159 Rattus Species 0.000 description 13
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 12
- 239000012458 free base Substances 0.000 description 10
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 10
- 230000001988 toxicity Effects 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000002411 adverse Effects 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 8
- 231100000607 toxicokinetics Toxicity 0.000 description 8
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 7
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 6
- 235000019253 formic acid Nutrition 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 210000004561 lacrimal apparatus Anatomy 0.000 description 5
- 229960005181 morphine Drugs 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 238000000132 electrospray ionisation Methods 0.000 description 4
- 235000020937 fasting conditions Nutrition 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 238000009533 lab test Methods 0.000 description 4
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 4
- 238000002552 multiple reaction monitoring Methods 0.000 description 4
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000440 toxicity profile Toxicity 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 206010011953 Decreased activity Diseases 0.000 description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 238000011887 Necropsy Methods 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 102000014823 calbindin Human genes 0.000 description 3
- 108060001061 calbindin Proteins 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 230000003544 deproteinization Effects 0.000 description 3
- 239000010432 diamond Substances 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010012225 Delirium tremens Diseases 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010028347 Muscle twitching Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 150000008134 glucuronides Chemical class 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 102000048260 kappa Opioid Receptors Human genes 0.000 description 2
- 239000004571 lime Substances 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000051367 mu Opioid Receptors Human genes 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000002385 psychotomimetic effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100001072 toxicokinetic profile Toxicity 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- 108020001588 κ-opioid receptors Proteins 0.000 description 2
- 108020001612 μ-opioid receptors Proteins 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000022497 Cocaine-Related disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 206010027646 Miosis Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000026251 Opioid-Related disease Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038669 Respiratory arrest Diseases 0.000 description 1
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241001246918 Tabernanthe iboga Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000002512 anti-withdrawal effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 239000001058 brown pigment Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 201000006145 cocaine dependence Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 108010022541 nicotinic receptor alpha3beta4 Proteins 0.000 description 1
- 238000002577 ophthalmoscopy Methods 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 238000002496 oximetry Methods 0.000 description 1
- 238000001441 oximetry spectrum Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000018052 penile erection Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011886 postmortem examination Methods 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 231100001271 preclinical toxicology Toxicity 0.000 description 1
- 238000002106 pulse oximetry Methods 0.000 description 1
- 230000001179 pupillary effect Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000001052 yellow pigment Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
Definitions
- the disclosure relates to the treatment of drug withdrawal symptoms.
- Ibogaine has been used as a botanical preparation from the root bark of iboga tabernathe for over 100 years both as a crude preparation and as semisynthetic ibogaine, which was marketed in France until about 1970. Observations in the 1970's suggested that ibogaine in higher doses was useful as a treatment for addiction. The use of ibogaine as a treatment for addiction was controversial because higher closes caused hallucinations and, in spite of many anecdotal reports of striking efficacy, no double-blind, placebo-controlled trials supported the efficacy of ibogaine as a treatment for withdrawal or addiction.
- U.S. Pat. No. 6,348,456 discloses highly purified noribogaine and teaches that it should be provided at dosages from about 0.01 to about 100 mg per kg body weight per day.
- noribogaine can cause convulsions and other CNS-related clinical signs, respiratory arrest and death. Given the signs of efficacy that noribogaine has shown, there is a need for a method to administer noribogaine in dosages that provide efficacy without leading to any significant deleterious clinical signs.
- the disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs.
- Such dosages provide maximum scrum concentrations (C max ) of noribogaine of less than about 2000 ng/mL, while maintaining efficacious average noribogaine serum levels of between about 100-2000 ng/mL (AUC/T).
- One embodiment of disclosure provides a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a C max of noribogaine of less than about 1980 ng/mL serum and an average AUC/24 hr of about 1,100 ng/mL.
- the patient is administered a dosage of noribogaine from about 100 mg to about 500 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 400 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 300 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 200 mg at intervals of about 24 hours.
- the patient is administered a dosage of noribogaine from about 200 mg to about 500 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 200 mg to about 400 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 200 mg to about 300 mg at intervals of about 24 hours.
- the patient is administered a dosage of noribogaine from about 300 mg to about 500 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 300 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 400 mg to about 500 mg at intervals of about 24 hours.
- FIG. 1 represents mean noribogaine concentration-lime profiles after single oral dosing with 3, 10, 30 or 60 mg doses.
- Inset Individual concentration-time profiles from 0-12 h alter a 10 mg dose.
- FIG. 2 represents mean plasma noribogaine glucuronide concentration-time profiles after single oral 30 or 60 mg doses.
- FIG. 3 represents mean noribogaine concentration-time profile in opioid-addicted patients after single oral 60 mg dose of noribogaine (gray diamonds).
- Mean noribogaine concentration-time profile in opioid-addicted patients after single oral 120 mg dose of noribogaine (black squares) was estimated based on values for patients receiving 60 mg dose.
- FIG. 4A represents hours to resumption of opioid substitution treatment in patients given no treatment (light gray bar), or a single dose of noribogaine or placebo (60 mg, dark gray bar; 120 mg, black bar). Error bars represent standard deviation.
- FIG. 4B represents the estimated serum noribogaine concentration in ng/mL at time of resumption of opioid substitution treatment (OST) in patients receiving single oral 60 mg dose of noribogaine (gray diamonds) or single oral 120 mg dose of noribogaine (black squares).
- OST opioid substitution treatment
- FIG. 5A represents hours to resumption of opioid substitution treatment in patients given no treatment (light gray bar), or a single 120 mg dose of noribogaine (black bar). Error bars represent standard deviation.
- FIG. 5B represents the estimated serum noribogaine concentration in ng/mL at time of resumption of opioid substitution treatment (OST) in patients receiving single oral 120 mg dose of noribogaine (black squares).
- OST opioid substitution treatment
- the disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs.
- Such dosages provide maximum serum concentrations (C max ) of noribogaine of less than about 2000 ng/mL, while maintaining efficacious average noribogaine serum levels of between about 100-1100 ng/ml (AUC/24 hr).
- noribogaine refers to noribogaine as well as its pharmaceutically acceptable salts.
- the methods of the present disclosure entail the administration of a prodrug of noribogaine that provides the desired maximum serum concentrations and efficacious average noribogaine serum levels.
- a prodrug of noribogaine refers to a compound that metabolizes, in vivo, to noribogaine.
- the prodrug is selected to be readily cleavage either by a cleavable linking arm or by cleavage of the prodrug entity that binds to noribogaine such that noribogaine is generated in vivo.
- the prodrug moiety is selected to facilitate binding to the ⁇ and/or ⁇ receptors in the brain either by facilitating passage across the blood brain barrier or by targeting brain receptors other than the ⁇ and/or ⁇ receptors.
- Examples of prodrugs of noribogaine are provided in U.S. patent application Ser. No. 13/165,626, the content of which is incorporated here by reference.
- the dosages administered provide a C max of noribogaine of less than about 1980 ng/mL serum and an average AUC/24 hr of about 1,100 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 1800 ng/mL serum and an AUC/24 hr of about 1000 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 1620 ng/mL serum and an AUC/24 hr of about 900 ng/mL.
- the dosages administered provide a C max of noribogaine of less than about 1440 ng/mL serum and an AUC/24 hr of about 800 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 1260 ng/mL serum and an AUC/24 hr of about 700 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 1400 ng/mL serum and an AUC/24 hr of from about 600 ng/mL.
- the dosages administered provide a C max of noribogaine of less than about 900 ng/mL serum and an AUC/24 hr of about 500 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 720 ng/mL serum and an AUC/24 hr of about 400 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 540 ng/mL serum and an AUC/24 hr of about 300 ng/mL.
- the dosages administered provide a C max of noribogaine of less than about 360 ng/mL serum and an AUC/24 hr of about 200 ng/mL. In certain embodiments, the dosages administered provide a C max of noribogaine of less than about 180 ng/mL serum and an AUC/24 hr of about 100 ng/mL.
- such concentrations are obtained by administering from about 100 to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 200 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 300 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 400 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 500 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 600 mg to about 1,100 mg at intervals of about 24 hours.
- such concentrations are obtained by administering from about 700 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 800 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 900 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 1,000 mg to about 1,100 mg at intervals of about 24 hours.
- such concentrations are obtained by administering from about 100 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 1,000 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 900 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 800 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 700 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 600 mg at intervals of about 24 hours.
- such concentrations are obtained by administering from about 100 mg to about 500 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 400 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 300 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 200 mg at intervals of about 24 hours.
- each patient is administered from about 100 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 100 mg to about 500 mg at intervals of about 24 hours, in some embodiments each patient is administered from about 100 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 100 mg to about 300 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 100 mg to about 200 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 500 mg at intervals of about 24 hours.
- each patient is administered from about 200 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 400 mg at intervals of about 24. hoursIn some embodiments each patient is administered from about 200 mg to about 300 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 300 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 300 mg to about 500 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 300 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 400 mg to about 500 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 400 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 500 mg to about 600 mg at intervals of about 24 hours.
- the patient is administered periodically, such as once, twice, three time, tour times or five time daily with noribogaine or its prodrug.
- the administration is once daily, or once every second day, once every third day, three times a week, twice a week, or once a week.
- the dosage and frequency of the administration depends on the route of administration, content of composition, age and body weight of the patient, condition of the patient, without limitation. Determination of dosage and frequency suitable for the present technology can be readily made a qualified clinician.
- noribogaine or its prodrug which may conveniently be provided in tablet, caplet, liquid or capsule form
- the noribogaine is provided as noribogaine HCl, with dosages reported as the amount of free base noribogaine.
- the noribogaine HCl is provided in hard gelatin capsules containing only noribogaine HCl with no excipients.
- noribogaine provides its anti-withdrawal symptom effects by acting as both an ⁇ 3 ⁇ 4 nicotinic receptor and a serotonin reuptake blocker acting on the 5-HT Transporter.
- the objective of this study was to determine the toxicity and toxicokinetic profile of noribogaine HCl following a single oral (gavage) administration in the Sprague-Dawley rat.
- a single dose of 100, 300 and 800 mg/kg (achieved with doses of 400 mg/kg 3 h+/ ⁇ 30 min apart because of the limitations of maximum dose formulation concentration).
- Five male rats/group were used. Mortality occurred in all male rats in the 800 mg/kg group, approximately 2-3 h after administration of the second dose of 400 mg/kg.
- hypoactivity, vocalization, salivation, stimuli sensitivity, loss of limb function and lying on the cage floor occurred on the day of treatment and persisted until Day 2 in 3/5 rats given 300 mg/kg.
- the low dose rats treated at 100 mg/kg did not show any treatment related signs.
- the NOAEL was determined to be 100 mg/kg.
- the objective of the study was to determine the toxicity and toxicokinetic profile of noribogaine following oral (gavage) administration to the cynomolgus monkey.
- the test article was administered as follows in Table 1:
- MTD maximum tolerated dose
- mice Male and female Sprague-Dawley rats, 10/sex/group, were administered 0, 25, 50 or 100 mg/kg noribogaine HCl daily by single oral gavage for 14 days. An additional 5 rats/sex/group in the 0 (control) and 100 mg/kg groups were retained for a 28 day recovery period during which no drug was administered. Six rats/sex/group (3 rats/sex controls) were similarly dosed and sampled on study days 1 and 14 for analysis of noribogaine-HCl concentrations in the blood.
- Rats were observed for mortality, clinical signs, body weight, food consumption, ophthalmology (pre-dose, during week 2, and at the end of recovery), hematology, coagulation, clinical chemistry, urinalysis, gross necropsy, organ weights and histopathology (full tissue panel, plus immunocytochemistry of 5 sections of the brain and spinal cord by staining for GFAP and Calbindin). There were no test article-related effects on mortality (none occurred), clinical signs, ophthalmoscopy, hematology, coagulation parameters, clinical chemistry, urinalysis, gross necropsy or histopathology.
- NOAEL dose in this study was interpreted to be 100 mg/kg, the highest dose tested in the study.
- Noribogaine HCl was administered to groups of 4 male and 4 female dogs by single oral gavage daily for 14 days at doses of 0, 0.5, 1.0 and 5.0 mg/kg/day.
- An additional group of 4 male and 4 female dogs received either the vehicle control or 5.0 mg/kg/day for 14 days and were held for an additional 28 days after cessation of dosing to assess recovery from any potential drug-induced changes.
- the study was conducted under GLP guidelines and included comprehensive examinations of clinical signs, body weight, clinical pathology parameters, ophthalmologic examinations. ECG recordings and analyses of plasma for bioanalytical measurement of drug levels at appropriate intervals during the study.
- the only target tissue identified in this study was the lacrimal gland of dogs receiving 5 mg/kg/day.
- the lacrimal gland changes were characterized by slight to moderate atrophy and degeneration of the acinar cells accompanied by slight to moderate accumulation of brown/yellow pigment and infiltration of mononuclear cells.
- ophthalmologic examination there was no clear association between these ocular signs and the appearance of the lacrimal gland changes suggesting that these morphologic changes did not result in sufficient functional abnormality of the gland to produce physical changes in exterior structures of the eye.
- the subject mean serum levels over time of noribogaine free base from a single dose of 3 mg noribogaine free base under fasting conditions were plotted.
- the mean C max of 5.2 ng/ml was observed 1.9 hours after administration, while the mean AUC/24 hr of 3.1 ng/ml was obtained.
- the subject mean serum levels over time of noribogaine free base from a single dose of 10 mg noribogaine free base under fasting conditions were plotted.
- the mean C max of 14.5 ng/ml was observed 2.9 hours after administration, while the mean AUC/24 hr of 10.6 ng/ml was obtained.
- the subject mean serum levels over time of noribogaine free base from a single dose of 30 mg noribogaine tree base under fasting conditions were plotted.
- the mean C max of 55.0 ng/ml was observed between 1.75 hours after administration, while the mean AUC/24 of 29.2 ng/ml was obtained.
- the subject mean serum levels over time of noribogaine free base from a single dose of 60 mg noribogaine free base under fasting conditions were plotted.
- the mean C max of 116 ng/ml was observed between 1.75 hours after administration, while the mean AUC/24 ng/ml of 61 was obtained.
- the subject mean scrum levels over time of noribogaine free base for all 4 cohorts were plotted.
- the extrapolated dosage of noribogaine free base required to provide a C max ranging from about 5.2 ng/ml to about 1980 ng/ml and an AUC/24 hr of about 3.1 ng/ml to about 1100 ng/ml was determined.
- Blood was obtained for pharmacokinetic assessments pre-dose and then at 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 14, 18, 24, 30, 36, 48, 60, 72, 96, 120, 168 and 216 hours post-dose. Samples were centrifuged and plasma stored at ⁇ 70° C. until analyzed. Block 24 hour urine collections were obtained following study drug administration for the 30 and 60 mg cohorts. Aliquots were frozen at ⁇ 20° C. until analyzed.
- Pulse oximetry and capnography data were collected continuously using a GE Carescape B650 monitoring system from 2 hours prior to dosing and until six hours after dosing, and thereafter at 12, 24, 48 and 72 hours post-dosing. Additional oximetry data were collected at 120, 168 and 216 hours.
- Pupillary miosis was assessed by pupillometry. Dark-adapted pupil diameter was measured in triplicate using a Neuroptics PLR-200 pupillometer under standardized light intensity ( ⁇ 5 lux) pre-dose, and at 2, 4, 6, 12, 24, 48, 72, 96, 120, 168 and 216 hours post-dosing.
- Plasma noribogaine concentrations were determined in the 3 mg and 10 mg dose groups using a validated, sensitive LCMSMS method.
- Sample preparation involved double extraction of basified plasma samples with tert-butyl methyl ether, drying the samples under a stream of nitrogen and reconstitution of sample with acetonitrile:B.P. water (5:95, v/v) containing 0.1% (v/v) formic acid.
- the compounds were separated by a 150 ⁇ 2.0 mm Luna 5 ⁇ m C18 column and detected with a triple-quadrupole API 4000 or 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring.
- Noribogaine-d 4 was used as the internal standard.
- the precursor-product ion transition values for noribogaine were m/z 297.6->122.3, and for the internal standard noribogaine-d 4 m/z 301.1->122.2.
- Analyst® software was used for data acquisition and processing.
- the ratio of the peak area of noribogaine to the internal standard noribogaine-d 4 was used for calibration and measurement of the unknown concentration of noribogaine.
- the lower limit of quantification (LLOQ) was 0.025 ng/ml noribogaine.
- the calibration curve was between 0.025 and 25.600 ng/ml noribogaine.
- Mobile phase A was acetonitrile:B.P.
- Plasma noribogaine concentrations were determined in the 30 mg and 60 mg dose groups using a validated, sensitive LCMSMS method.
- Sample preparation involved deproteinization of plasma samples with acetonitrile and dilution of sample with 0.1% (v/v) formic acid. The compounds were separated by a 150 ⁇ 2.0 mm Luna 5 ⁇ m C18 column and detected with a triple-quadrupole API 4000 or 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring.
- Noribogaine-d 4 was used as the internal standard.
- the precursor-product ion transition values for noribogaine were m/z 297.6->122.3, and for the internal standard noribogaine-d 4 m/z 301.1->122.2.
- Plasma noribogaine glucuronide concentrations were determined in the 30 mg and 60 mg dose groups using a validated sensitive LCMSMS method.
- Sample preparation involved deproteinization of plasma samples with acetonitrile. drying the samples under a stream of nitrogen and reconstitution of sample with acetonitrile:B.P. water (5:95, v/v) containing 0.1% (v/v) formic acid.
- the compounds were separated by a 150 ⁇ 2.0 mm Luna 5 ⁇ m CI 8 column and detected with a triple-quadrupole API 4000 or 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring.
- Noribogaine-d 4 was used as the internal standard.
- the precursor-product ion, transition values for noribogaine glucuronide were m/z 472.8>297.3, and for the internal standard noribogaine-d 4 m/z 301.1->122.2.
- Analyst® software was used for data acquisition and processing.
- the ratio of the peak area of noribogaine glucuronide to the internal standard noribogaine-d 4 was used for calibration and measurement of the unknown concentration of noribogaine glucuronide.
- the LLOQ was 0.050 ng/ml noribogaine glucuronide.
- the calibration curve was between 0.050 and 6,400 ng/ml noribogaine glucuronide.
- Mobile phases was the same as method A.
- Urine noribogaine and noribogaine glucuronide concentrations were determined in the 30 mg and 60 mg dose groups using a validated sensitive LCMSMS method.
- Sample preparation involved deproteinization of urine samples with acetonitrile and dilution of the sample with 0.1% (v/v) formic acid. The compounds were separated by a 150 ⁇ 2.0 mm Luna 5 ⁇ m C18 column and detected with a triple-quadrupole API 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring. Noribogaine-d 4 was used as the internal standard.
- the precursor-product ion transition values for noribogaine were m/z 297.6->122.3, noribogaine glucuronide m/z 472.8->297.3, and for the internal standard noribogaine-d 4 m/z 301.1->122.2.
- Analyst® software was used for data acquisition and processing.
- the ratios of the peak area of noribogaine and noribogaine glucuronide to the internal standard noribogaine-d 4 were used for calibration and measurement of the unknown concentration of noribogaine and its glucuronide.
- Assay LLOQ was 20.0 ng/ml for noribogaine and 2.0 ng/ml for noribogaine glucuronide.
- the calibration curve was between 20.0 and 5120.0 ng/ml noribogaine, and 2.0 and 512.0 ng/ml noribogaine glucuronide.
- Mobile phases were as described in method A, and binary flow as in method C.
- the within- and between-day assay precision was ⁇ 13%, and within- and between-day assay accuracy was ⁇ 12%.
- Noribogaine and noribogaine glucuronide concentrations above the limit of quantification were used to calculate pharmacokinetic parameters using model-independent methods.
- the maximum plasma concentration (Cmax) and time to maximum plasma concentration (Tmax) were the observed values.
- the area under the concentration-time curve (AUC) from time zero to the last determined concentration-time point (tf) in the post distribution phase was calculated using the trapezoidal rule.
- the concentration used for Ctf was the last determined value above the LLOQ at the time point.
- the total AUC 0- ⁇ was obtained by adding AUC 1f and AUC t- ⁇ .
- Total urine noribogaine was the sum of both analytes.
- Noribogaine was rapidly absorbed, with peak concentrations occurring 2-3 hours after oral dosing. Fluctuations in individual distribution-phase concentration-time profiles may suggest the possibility of enterohepatic recirculation (see highlighted individual 4-8 hour profiles in FIG. 1 , insert). Both Cmax and AUC increased linearly with dose (Table 6, upper panel). Mean half-life estimates of 28-50 hours were observed across dose groups for noribogaine. Volume of distribution was extensive (1417-3086 L across dose groups).
- Noribogaine treatment showed no analgesic effect in the cold pressor test.
- Analgesic effect was assessed based on duration of hand immersion in ice water and on visual analog scale (VAS) pain scores upon hand removal from the water bath.
- VAS visual analog scale
- Safety and tolerability of noribogaine were tested in the group of volunteers from Example 1. Cold pressor testing was conducted in 1° C. water according to the method of Mitchell et al. ( J Pain 5:233-237, 2004) pre-dose, 6, 24, 48, 72 and 216 hours post-dosing. Safety evaluations included clinical monitoring, recording of adverse events (AEs), safety laboratory tests, vital signs, ECO telemetry from ⁇ 2 h to 6 h after dosing, and 12-lead electrocardiograms (ECGs) up to 216 hours post-dosing.
- AEs adverse events
- ECGs 12-lead electrocardiograms
- noribogaine The efficacy of noribogaine in humans was evaluated in opioid-dependent participants in a randomized, placebo-controlled, double-blind trial.
- first cohort six patients were orally administered a single dose of 60 mg noribogaine, and three patients received placebo.
- second cohort five patients were orally administered a single dose of 120 mg noribogaine, and three patients received placebo.
- Treatment was administered 2 hours after last morphine dose and the time to resumption of morphine (opioid substitution treatment, OST) was determined. No adverse effects of noribogaine were observed in any of the participants, including no hallucinatory effects.
- FIG. 3 indicates the serum noribogaine concentration over time. Serum concentrations for 120 mg dose (black squares) are estimated based on data from the 60 mg dose (gray diamonds).
- FIG. 4A indicates the average time to resumption of morphine for control (untreated, light gray bar), first cohort (dark gray bar) and second cohort (black bar). Mean prolongation of the QT interval was less than 10 ms for patients in the first cohort and was less than 40 ms in the second cohort.
- FIG. 4B indicates the estimated noribogaine concentration (based on the data from FIG. 3 ) at the time of resumption of morphine for each patient.
- FIG. 5A black bar
- FIG. 5B indicates the estimated noribogaine concentration (based on the data from FIG. 3 ) at the time of resumption of morphine for each (presumed) noribogaine-treated patient.
Abstract
Description
- The disclosure relates to the treatment of drug withdrawal symptoms.
- Withdrawal from drug dependence is characterized by dramatic and traumatic symptoms, including sweating, racing heart, palpitations, muscle tension, tightness in the chest, difficulty breathing, tremor, nausea, vomiting, diarrhea, grand mal seizures, heart attacks, strokes, hallucinations and delirium tremens (DTs). Numerous treatments have been developed in attempts to ameliorate such symptoms.
- Ibogaine has been used as a botanical preparation from the root bark of iboga tabernathe for over 100 years both as a crude preparation and as semisynthetic ibogaine, which was marketed in France until about 1970. Observations in the 1970's suggested that ibogaine in higher doses was useful as a treatment for addiction. The use of ibogaine as a treatment for addiction was controversial because higher closes caused hallucinations and, in spite of many anecdotal reports of striking efficacy, no double-blind, placebo-controlled trials supported the efficacy of ibogaine as a treatment for withdrawal or addiction.
- U.S. Pat. No. 6,348,456 discloses highly purified noribogaine and teaches that it should be provided at dosages from about 0.01 to about 100 mg per kg body weight per day.
- More recently, the pharmacokinetics and metabolism of ibogaine was evaluated and it was found that the psychotomimetic effects correlated with blood levels of ibogaine, while the anti-addictive effects correlated with blood levels of noribogaine, the only metabolite of ibogaine found in humans, dogs, rats and monkeys. These experiments were followed up with animal studies of noribogaine in various addiction models, which demonstrated that noribogaine significantly reduced drug-seeking behavior and had no activity in an evaluation of psychotomimetic effects in an animal model. Noribogaine is now being developed as a treatment for the symptoms of drug addiction and has shown to be effective in animal models of addiction to alcohol, cocaine and opiate dependence.
- During pre-clinical toxicity studies in various animal species, it was found that high doses of noribogaine can cause convulsions and other CNS-related clinical signs, respiratory arrest and death. Given the signs of efficacy that noribogaine has shown, there is a need for a method to administer noribogaine in dosages that provide efficacy without leading to any significant deleterious clinical signs.
- The disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs. Such dosages provide maximum scrum concentrations (Cmax) of noribogaine of less than about 2000 ng/mL, while maintaining efficacious average noribogaine serum levels of between about 100-2000 ng/mL (AUC/T).
- One embodiment of disclosure provides a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 1980 ng/mL serum and an average AUC/24 hr of about 1,100 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 1800 ng/mL serum and an AUC/24 hr of about 1000 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 1620 ng/mL serum and an AUC/24 hr of about 900 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 1440 ng/mL serum and an AUC/24 hr of about 800 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 1260 ng/mL serum and an AUC/24 hr of about 700 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 1400 ng/mL serum and an AUC/24 hr of from about 600 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 900 ng/mL serum and an AUC/24 hr of about 500 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 720 ng/mL serum and an AUC/24 hr of about 400 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 540 ng/mL serum and an AUC/24 hr of about 300 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 360 ng/mL serum and an AUC/24 hr of about 200 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine that provides a Cmax of noribogaine of less than about 180 ng/mL serum and an AUC/24 hr of about 100 ng/mL.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine from about 100 mg to about 600 mg at intervals of about 24 hours.
- In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 500 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 400 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 300 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 100 mg to about 200 mg at intervals of about 24 hours.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine from about 200 mg to about 600 mg at intervals of about 24 hours.
- In some embodiments, the patient is administered a dosage of noribogaine from about 200 mg to about 500 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 200 mg to about 400 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 200 mg to about 300 mg at intervals of about 24 hours.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine from about 300 mg to about 600 mg at intervals of about 24 hours.
- In some embodiments, the patient is administered a dosage of noribogaine from about 300 mg to about 500 mg at intervals of about 24 hours. In some embodiments, the patient is administered a dosage of noribogaine from about 300 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 400 mg to about 500 mg at intervals of about 24 hours.
- Also provided, in one embodiment, is a method for treating withdrawal symptoms in a patient suffering from withdrawal from addiction to a substance comprising administering to the patient a dosage of noribogaine from about 500 mg to about 600 mg at intervals of about 24 hours.
-
FIG. 1 represents mean noribogaine concentration-lime profiles after single oral dosing with 3, 10, 30 or 60 mg doses. Inset: Individual concentration-time profiles from 0-12 h alter a 10 mg dose. -
FIG. 2 represents mean plasma noribogaine glucuronide concentration-time profiles after single oral 30 or 60 mg doses. -
FIG. 3 represents mean noribogaine concentration-time profile in opioid-addicted patients after single oral 60 mg dose of noribogaine (gray diamonds). Mean noribogaine concentration-time profile in opioid-addicted patients after single oral 120 mg dose of noribogaine (black squares) was estimated based on values for patients receiving 60 mg dose. -
FIG. 4A represents hours to resumption of opioid substitution treatment in patients given no treatment (light gray bar), or a single dose of noribogaine or placebo (60 mg, dark gray bar; 120 mg, black bar). Error bars represent standard deviation. -
FIG. 4B represents the estimated serum noribogaine concentration in ng/mL at time of resumption of opioid substitution treatment (OST) in patients receiving single oral 60 mg dose of noribogaine (gray diamonds) or single oral 120 mg dose of noribogaine (black squares). -
FIG. 5A represents hours to resumption of opioid substitution treatment in patients given no treatment (light gray bar), or a single 120 mg dose of noribogaine (black bar). Error bars represent standard deviation. -
FIG. 5B represents the estimated serum noribogaine concentration in ng/mL at time of resumption of opioid substitution treatment (OST) in patients receiving single oral 120 mg dose of noribogaine (black squares). - The disclosure provides a method to administer noribogaine to a human patient having drug addiction in dosages that provide efficacy without leading to any significant deleterious clinical signs. Such dosages provide maximum serum concentrations (Cmax) of noribogaine of less than about 2000 ng/mL, while maintaining efficacious average noribogaine serum levels of between about 100-1100 ng/ml (AUC/24 hr).
- The term “noribogaine” as used herein, refers to noribogaine as well as its pharmaceutically acceptable salts. In some embodiments, the methods of the present disclosure entail the administration of a prodrug of noribogaine that provides the desired maximum serum concentrations and efficacious average noribogaine serum levels. A prodrug of noribogaine refers to a compound that metabolizes, in vivo, to noribogaine. In some embodiment, the prodrug is selected to be readily cleavage either by a cleavable linking arm or by cleavage of the prodrug entity that binds to noribogaine such that noribogaine is generated in vivo. In one preferred embodiment, the prodrug moiety is selected to facilitate binding to the μ and/or κ receptors in the brain either by facilitating passage across the blood brain barrier or by targeting brain receptors other than the μ and/or κ receptors. Examples of prodrugs of noribogaine are provided in U.S. patent application Ser. No. 13/165,626, the content of which is incorporated here by reference.
- The following ranges are obtained from a single dose of noribogaine HCl/fasting patient.
- In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 1980 ng/mL serum and an average AUC/24 hr of about 1,100 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 1800 ng/mL serum and an AUC/24 hr of about 1000 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 1620 ng/mL serum and an AUC/24 hr of about 900 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 1440 ng/mL serum and an AUC/24 hr of about 800 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 1260 ng/mL serum and an AUC/24 hr of about 700 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 1400 ng/mL serum and an AUC/24 hr of from about 600 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 900 ng/mL serum and an AUC/24 hr of about 500 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 720 ng/mL serum and an AUC/24 hr of about 400 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 540 ng/mL serum and an AUC/24 hr of about 300 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 360 ng/mL serum and an AUC/24 hr of about 200 ng/mL. In certain embodiments, the dosages administered provide a Cmax of noribogaine of less than about 180 ng/mL serum and an AUC/24 hr of about 100 ng/mL.
- In some embodiments such concentrations are obtained by administering from about 100 to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 200 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 300 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 400 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 500 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 600 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 700 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 800 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 900 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 1,000 mg to about 1,100 mg at intervals of about 24 hours.
- In some embodiments such concentrations are obtained by administering from about 100 mg to about 1,100 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 1,000 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 900 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 800 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 700 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 600 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 500 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 400 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 300 mg at intervals of about 24 hours. In some embodiments such concentrations are obtained by administering from about 100 mg to about 200 mg at intervals of about 24 hours.
- Particularly preferred embodiments include the following dose ranges. In some embodiments each patient is administered from about 100 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 100 mg to about 500 mg at intervals of about 24 hours, in some embodiments each patient is administered from about 100 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 100 mg to about 300 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 100 mg to about 200 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 500 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 200 mg to about 400 mg at intervals of about 24. hoursIn some embodiments each patient is administered from about 200 mg to about 300 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 300 mg to about 400 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 300 mg to about 500 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 300 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 400 mg to about 500 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 400 mg to about 600 mg at intervals of about 24 hours. In some embodiments each patient is administered from about 500 mg to about 600 mg at intervals of about 24 hours.
- In some embodiments, the patient is administered periodically, such as once, twice, three time, tour times or five time daily with noribogaine or its prodrug. In some embodiments, the administration is once daily, or once every second day, once every third day, three times a week, twice a week, or once a week. The dosage and frequency of the administration depends on the route of administration, content of composition, age and body weight of the patient, condition of the patient, without limitation. Determination of dosage and frequency suitable for the present technology can be readily made a qualified clinician.
- These dose ranges are achieved by oral administration of noribogaine or its prodrug, which may conveniently be provided in tablet, caplet, liquid or capsule form, in certain embodiments, the noribogaine is provided as noribogaine HCl, with dosages reported as the amount of free base noribogaine. In some embodiments, the noribogaine HCl is provided in hard gelatin capsules containing only noribogaine HCl with no excipients.
- Without wishing to be bound by theory, it is believed that noribogaine provides its anti-withdrawal symptom effects by acting as both an α3β4 nicotinic receptor and a serotonin reuptake blocker acting on the 5-HT Transporter.
- The following Examples are intended to further illustrate certain embodiments of the disclosure and are not intended to limit its scope.
- The objective of this study was to determine the toxicity and toxicokinetic profile of noribogaine HCl following a single oral (gavage) administration in the Sprague-Dawley rat. A single dose of 100, 300 and 800 mg/kg (achieved with doses of 400 mg/kg 3 h+/−30 min apart because of the limitations of maximum dose formulation concentration). Five male rats/group were used. Mortality occurred in all male rats in the 800 mg/kg group, approximately 2-3 h after administration of the second dose of 400 mg/kg. Hypoactivity, vocalization, chewing movements, changes in respiration/posture, salivation, stimuli sensitivity, tremors, twitches and penile erection occurred prior to death. Hypoactivity, vocalization, salivation, stimuli sensitivity, loss of limb function and lying on the cage floor occurred on the day of treatment and persisted until
Day 2 in 3/5 rats given 300 mg/kg. The low dose rats treated at 100 mg/kg did not show any treatment related signs. The NOAEL was determined to be 100 mg/kg. - In an acute oral toxicity/TK study in dogs, no mortality occurred at doses of 5 (n=2) or 10 (n=2) mg/kg. Convulsions and other CNS-related clinical signs, including twitches, salivation, vocalization, incoordination and hypoactivity, occurred at a dose of 10 mg/kg, beginning 20 minutes after dosing and persisting until 3 h 40 m post-dose. The 5 mg/kg dose was considered the NOAEL, as only transient reduction in food consumption in one dog occurred at that dose.
- The objective of the study was to determine the toxicity and toxicokinetic profile of noribogaine following oral (gavage) administration to the cynomolgus monkey. The test article was administered as follows in Table 1:
-
TABLE 1 Toxicity and Toxicokinetic Study in Cynomolgus monkeys Treatment on Study Day Dose Level (mg/kg) Number of Animals 1 20 2 males 8 40 2 males 15 80 and 160 2 males * = Each dose was followed by a 7 day washout period. Dosing was staggered by 45 minutes. ** = One animal was administered 80 mg/kg and the other animal was administered 160 mg/kg. - Parameters monitored on the study included: mortality, clinical signs and body weights. Blood samples were collected for TK evaluation. No mortality or treatment related clinical signs were noted for doses up to and including 160 mg/kg. The single dose maximum tolerated dose (MTD) was determined to be greater than 160 mg/kg based on the parameters monitored during the study.
- This study was conducted to evaluate the toxicity profile of noribogaine-HCl following oral (gavage) administration to the rat for 14 days following Table 2 below:
-
TABLE 2 Toxicity and Toxicokinetic Study in Rats Dose Concen- Toxicology Animals Toxicokinetics Dose Level tration Main Recovery Animals Group (mg/kg/day) (mg/mL) Male Female Male Female Male Female Control 0 0 10 10 5 5 3 3 Low Dose 25 5 10 10 — — 6 6 Mid Dose 50 10 10 10 — — 6 6 High Dose 100 20 10 10 5 5 6 6 - Male and female Sprague-Dawley rats, 10/sex/group, were administered 0, 25, 50 or 100 mg/kg noribogaine HCl daily by single oral gavage for 14 days. An additional 5 rats/sex/group in the 0 (control) and 100 mg/kg groups were retained for a 28 day recovery period during which no drug was administered. Six rats/sex/group (3 rats/sex controls) were similarly dosed and sampled on
study days 1 and 14 for analysis of noribogaine-HCl concentrations in the blood. Rats were observed for mortality, clinical signs, body weight, food consumption, ophthalmology (pre-dose, duringweek 2, and at the end of recovery), hematology, coagulation, clinical chemistry, urinalysis, gross necropsy, organ weights and histopathology (full tissue panel, plus immunocytochemistry of 5 sections of the brain and spinal cord by staining for GFAP and Calbindin). There were no test article-related effects on mortality (none occurred), clinical signs, ophthalmoscopy, hematology, coagulation parameters, clinical chemistry, urinalysis, gross necropsy or histopathology. Food consumption and body weight were slightly reduced (food consumption: −4.7% in males and females: body weight: −5.5% in males and −2.6% in females) in the high dose (100 mg/kg) groups. Minor increases in liver weight in the mid- and high close groups were not correlated with histopathologic changes and are considered incidental. No treatment-related differences in the brain were seen in sections stained for GFAP or Calbindin. - The NOAEL dose in this study was interpreted to be 100 mg/kg, the highest dose tested in the study.
- The objective of this study was to determine the toxicity profile of noribogaine HCl given following oral (gavage) administration to dogs for 14 days according to the following Table 3 below:
-
TABLE 3 Toxicity and Toxicokinetic Study in Dogs Dose Group Concen- Toxicology Animals Desig- Dose Level tration Main Recovery nation (mg/kg/day) (mg/mL) Male Female Male Female Control 0 0 4 4 4 4 Low Dose 0.5 0.1 4 4 — — Mid Dose 1.0 0.2 4 4 — — High Dose 5.0 1.0 4 4 4 4 - Noribogaine HCl was administered to groups of 4 male and 4 female dogs by single oral gavage daily for 14 days at doses of 0, 0.5, 1.0 and 5.0 mg/kg/day. An additional group of 4 male and 4 female dogs received either the vehicle control or 5.0 mg/kg/day for 14 days and were held for an additional 28 days after cessation of dosing to assess recovery from any potential drug-induced changes. The study was conducted under GLP guidelines and included comprehensive examinations of clinical signs, body weight, clinical pathology parameters, ophthalmologic examinations. ECG recordings and analyses of plasma for bioanalytical measurement of drug levels at appropriate intervals during the study. At the termination of the dosing phase and at the termination of the recovery phase, all dogs were subjected to a complete post-mortem examination including gross examination of major organs and histologic examination of an extensive list of tissues. Additional sections of brain were obtained from cerebrum, cerebellus, brain stem and spinal cord and examined histologically to evaluate potential effects on brain histopathology. In addition, these sections were examined with immunohistochemical stains for GFAP for evidence of gliosis and Calbindin for a more comprehensive examination of cerebellar Purkinje cells. No evidence of adverse effect was observed in any dog from any treatment group during the dosing or recovery phase in clinical observations, body weights, clinical pathological parameters, ophthalmologic examinations, ECG recordings, or gross lesions at necropsy. The results of the plasma drug level measurements at Day 1 and
Day 14 of the study are shown in Tables 4 and 5 below. Noribogaine-HCl maximum plasma concentrations (Cmax) were reached between 0.5 and 0.9 hours post-dosing, following which plasma concentrations gradually decreased over a period of up to 24 hours, except in the male dogs and female dogs ofGroup 4, for which significant levels of noribogaine were still detected at 24 h post-dosing on bothDays 1 and 14. - The only target tissue identified in this study was the lacrimal gland of dogs receiving 5 mg/kg/day. The lacrimal gland changes were characterized by slight to moderate atrophy and degeneration of the acinar cells accompanied by slight to moderate accumulation of brown/yellow pigment and infiltration of mononuclear cells. There was an associated mononuclear infiltration in the draining mandibular lymph nodes of affected dogs in this dose group. Despite the appearance of isolated ocular abnormalities in several dogs in this high dose group on ophthalmologic examination, there was no clear association between these ocular signs and the appearance of the lacrimal gland changes suggesting that these morphologic changes did not result in sufficient functional abnormality of the gland to produce physical changes in exterior structures of the eye. There was no clear evidence of local irritation associated with drug treatment in these high dose dogs. No evidence of drug-induced effect was observed in any other tissue including the extensive sections of brain evaluated with conventional histopathology or with immunohistochemistry. Examination of the animals in the recovery group showed clear evidence of regeneration of this lacrimal gland change. While slight atrophy was still evident in the acinar cells of the gland after 28 days off drug, no evidence of continuing and ongoing degeneration or cellular infiltration was observed. The NOAEL in this study was 1 mg/kg/day based on the lacrimal gland changes at 5 mg/kg/day. The results are summarized in Tables 4 and 5.
-
TABLE 4 Mean plasma toxicokinetic parameters for noribogaine in male dogs on days 1 and 14Gr 2 - 0.5 mg/kg Gr 3 - 1.0 mg/kg Gr 4 - 5.0 mg/kg Parameters D1 D14 D1 D14 D1 D14 T1/2 (h) 1.3 1.3 1.2 1.8 4.7 6.5 Tmax (h) 0.7 0.7 0.9 0.8 0.6 0.9 Cmax (ng/ml) 28.8 29.4 58.6 67.6 693 716 AUC0-last 46.6 53.2 102.5 172.3 3515.0 6403.3 (hr*ng/ml) AUC0-24 h 59.7 64.5 119.8 210.4 3515.0 6403.3 (hr*ng/ml) AUC0-∞ 67.8 68.2 120.8 195.7 3630.5 6961.4 (hr*ng/ml) -
TABLE 5 Mean plasma toxicokinetic parameters for noribogaine in fermale dogs on days 1 and 14Gr 2 - 0.5 mg/kg Gr 3 - 1.0 mg/kg Gr 4 - 5.0 mg/kg Parameters D1 D14 D1 D14 D1 D14 T1/2 (hr) 1.0 1.1 1.4 1.6 4.3 5.7 Tmax (hr) 0.5 1.0 0.8 0.5 0.6 0.6 Cmax (ng/ml) 25.3 29.8 68.5 74.1 691 683 AUC0-last 31.5 35.4 148.9 169.0 3367.9 5951.2 (hr*ng/ml) AUC0-24 h 40.4 55.0 176.2 203.7 3367.9 5951.2 (hr*ng/ml) AUC0-∞ 44.9 45.7 165.3 197.0 3425.7 6283.2 (hr*ng/ml) - In double blind studies, fasting healthy volunteers (6 per cohort) were treated once orally with a tablet of noribogaine HCl. In escalating cohorts, the volunteers received 3 mg, 10 mg, 30 mg or 60 mg noribogaine. The results are provided below. All parameters were linear and no clinically relevant adverse effects were observed in the trial.
- The subject mean serum levels over time of noribogaine free base from a single dose of 3 mg noribogaine free base under fasting conditions were plotted. The mean Cmax of 5.2 ng/ml was observed 1.9 hours after administration, while the mean AUC/24 hr of 3.1 ng/ml was obtained.
- The subject mean serum levels over time of noribogaine free base from a single dose of 10 mg noribogaine free base under fasting conditions were plotted. The mean Cmax of 14.5 ng/ml was observed 2.9 hours after administration, while the mean AUC/24 hr of 10.6 ng/ml was obtained.
- The subject mean serum levels over time of noribogaine free base from a single dose of 30 mg noribogaine tree base under fasting conditions were plotted. The mean Cmax of 55.0 ng/ml was observed between 1.75 hours after administration, while the mean AUC/24 of 29.2 ng/ml was obtained.
- The subject mean serum levels over time of noribogaine free base from a single dose of 60 mg noribogaine free base under fasting conditions were plotted. The mean Cmax of 116 ng/ml was observed between 1.75 hours after administration, while the mean AUC/24 ng/ml of 61 was obtained.
- The subject mean scrum levels over time of noribogaine free base for all 4 cohorts were plotted. The extrapolated dosage of noribogaine free base required to provide a Cmax ranging from about 5.2 ng/ml to about 1980 ng/ml and an AUC/24 hr of about 3.1 ng/ml to about 1100 ng/ml was determined.
- Thirty-six healthy, drug-free male volunteers, aged between 18-55 years, were enrolled in and completed the study. This was an ascending single-dose, placebo-controlled, randomised double blind, parallel group study. Mean (SD) age was 22.0 (3.3) years, mean (SD) height was 1.82 (0.08) m, and mean (SD) weight was 78.0 (9.2) kg. Twenty-six subjects were Caucasian, 3 were Asian, 1 Maori, 1 Pacific Islander, and 5 Other. The protocol for this study was approved by the Lower South Regional Ethics Committee (LRS/12/06/015), and the study was registered with the Australian New Zealand Clinical Trial Registry (ACTRN12612000821897). All subjects provided signed informed consent prior to enrolment, and were assessed as suitable to participate based on review of medical history, physical examination, safety laboratory tests, vital signs and ECG.
- Within each dose level, 6 participants were randomized to receive noribogaine and 3 to receive placebo, based on a computer-generated random code. Dosing began with the lowest noribogaine dose, and subsequent cohorts received the next highest dose after the safety, tolerability, and blinded pharmacokinetics of the completed cohort were reviewed and dose-escalation approved by an independent Data Safety Monitoring Board. Blinded study drug was administered as a capsule with 240 ml of water after an overnight fast of at least 10 hours. Participants did not receive any food until at least 5 hours post-dose. Participants were confined to the study site from 12 hours prior to drug administration, until 72 hours post-dose, and there were subsequent outpatient assessments until 216 hours post-dose.
- Blood was obtained for pharmacokinetic assessments pre-dose and then at 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 7, 8, 10, 12, 14, 18, 24, 30, 36, 48, 60, 72, 96, 120, 168 and 216 hours post-dose. Samples were centrifuged and plasma stored at −70° C. until analyzed.
Block 24 hour urine collections were obtained following study drug administration for the 30 and 60 mg cohorts. Aliquots were frozen at −20° C. until analyzed. - Pulse oximetry and capnography data were collected continuously using a GE Carescape B650 monitoring system from 2 hours prior to dosing and until six hours after dosing, and thereafter at 12, 24, 48 and 72 hours post-dosing. Additional oximetry data were collected at 120, 168 and 216 hours. Pupillary miosis was assessed by pupillometry. Dark-adapted pupil diameter was measured in triplicate using a Neuroptics PLR-200 pupillometer under standardized light intensity (<5 lux) pre-dose, and at 2, 4, 6, 12, 24, 48, 72, 96, 120, 168 and 216 hours post-dosing.
- Plasma noribogaine concentrations were determined in the 3 mg and 10 mg dose groups using a validated, sensitive LCMSMS method. Sample preparation involved double extraction of basified plasma samples with tert-butyl methyl ether, drying the samples under a stream of nitrogen and reconstitution of sample with acetonitrile:B.P. water (5:95, v/v) containing 0.1% (v/v) formic acid. The compounds were separated by a 150×2.0
mm Luna 5 μm C18 column and detected with a triple-quadrupole API 4000 or 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring. Noribogaine-d4 was used as the internal standard. The precursor-product ion transition values for noribogaine were m/z 297.6->122.3, and for the internal standard noribogaine-d4 m/z 301.1->122.2. Analyst® software was used for data acquisition and processing. The ratio of the peak area of noribogaine to the internal standard noribogaine-d4 was used for calibration and measurement of the unknown concentration of noribogaine. The lower limit of quantification (LLOQ) was 0.025 ng/ml noribogaine. The calibration curve was between 0.025 and 25.600 ng/ml noribogaine. Mobile phase A was acetonitrile:B.P. water (5:95, v/v) containing 0.1% (v/v) formic acid, and mobile phase B was acetonitrile:B.P. water (95:5, v/v) containing 0.1% (v/v) formic acid. Total run time was 6 minutes. Binary flow: Initial concentration was 8% mobile phase B; hold at 8% mobile phase B for 0.5 minutes and linear rise to 90% mobile phase B over 1.5 minutes; hold at 90% mobile phase B for 1 minute and then drop back to 8% mobile phase B over 0.01 minute. Equilibrate system for 3 minutes. Total run time was 6 minutes. Within- and between-day assay precision was <9%, and within- and between-day assay accuracy was <9%. - Plasma noribogaine concentrations were determined in the 30 mg and 60 mg dose groups using a validated, sensitive LCMSMS method. Sample preparation involved deproteinization of plasma samples with acetonitrile and dilution of sample with 0.1% (v/v) formic acid. The compounds were separated by a 150×2.0
mm Luna 5 μm C18 column and detected with a triple-quadrupole API 4000 or 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring. Noribogaine-d4 was used as the internal standard. The precursor-product ion transition values for noribogaine were m/z 297.6->122.3, and for the internal standard noribogaine-d4 m/z 301.1->122.2. Analyst® software was used for data acquisition and processing. The ratio of the peak area of noribogaine to the internal standard noribogaine-d4 was used for calibration and measurement of the unknown concentration of noribogaine. The LLOQ was 0.50 ng/ml noribogaine. The calibration curve was between 0.50 and 256.00 ng/ml noribogaine. Mobile phase was the same as method A, and binary flow was also the same as method A. The within- and between-day assay precision was <9%, and the within- and between-day assay accuracy was <9%. - Plasma noribogaine glucuronide concentrations were determined in the 30 mg and 60 mg dose groups using a validated sensitive LCMSMS method. Sample preparation involved deproteinization of plasma samples with acetonitrile. drying the samples under a stream of nitrogen and reconstitution of sample with acetonitrile:B.P. water (5:95, v/v) containing 0.1% (v/v) formic acid. The compounds were separated by a 150×2.0
mm Luna 5 μm CI 8 column and detected with a triple-quadrupole API 4000 or 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring. Noribogaine-d4 was used as the internal standard. The precursor-product ion, transition values for noribogaine glucuronide were m/z 472.8>297.3, and for the internal standard noribogaine-d4 m/z 301.1->122.2. Analyst® software was used for data acquisition and processing. The ratio of the peak area of noribogaine glucuronide to the internal standard noribogaine-d4 was used for calibration and measurement of the unknown concentration of noribogaine glucuronide. The LLOQ was 0.050 ng/ml noribogaine glucuronide. The calibration curve was between 0.050 and 6,400 ng/ml noribogaine glucuronide. Mobile phases was the same as method A. Binary flow: Initial concentration was 6% mobile phase B; hold at 6% mobile phase B for 0.5 minutes and linear rise to 90% mobile phase B over 2 minutes; hold at 90% mobile phase B for 1 minute and then drop back to 6% mobile phase B over 0.01 minute. Equilibrate system for 3.5 minutes. Total run time was 7 minutes. The within- and between-day assay precision was <11%, and the within- and between-day assay accuracy was <10%. - Urine noribogaine and noribogaine glucuronide concentrations were determined in the 30 mg and 60 mg dose groups using a validated sensitive LCMSMS method. Sample preparation involved deproteinization of urine samples with acetonitrile and dilution of the sample with 0.1% (v/v) formic acid. The compounds were separated by a 150×2.0
mm Luna 5 μm C18 column and detected with a triple-quadrupole API 5000 mass spectrometer using electrospray ionization in positive mode and multiple reaction monitoring. Noribogaine-d4 was used as the internal standard. The precursor-product ion transition values for noribogaine were m/z 297.6->122.3, noribogaine glucuronide m/z 472.8->297.3, and for the internal standard noribogaine-d4 m/z 301.1->122.2. Analyst® software was used for data acquisition and processing. The ratios of the peak area of noribogaine and noribogaine glucuronide to the internal standard noribogaine-d4 were used for calibration and measurement of the unknown concentration of noribogaine and its glucuronide. Assay LLOQ was 20.0 ng/ml for noribogaine and 2.0 ng/ml for noribogaine glucuronide. The calibration curve was between 20.0 and 5120.0 ng/ml noribogaine, and 2.0 and 512.0 ng/ml noribogaine glucuronide. Mobile phases were as described in method A, and binary flow as in method C. The within- and between-day assay precision was <13%, and within- and between-day assay accuracy was <12%. - Noribogaine and noribogaine glucuronide concentrations above the limit of quantification were used to calculate pharmacokinetic parameters using model-independent methods. The maximum plasma concentration (Cmax) and time to maximum plasma concentration (Tmax) were the observed values. Plasma concentration data in the post-distribution phase of the plasma concentration-time plot were fitted using linear regression to the formula ln C=ln Co−t·Kel, where Co was the zero-lime intercept of the extrapolated terminal phase and Kel was the terminal elimination rate constant. The half-life (t1/2) was determined using the formula t1/2=0.693/Kel. The area under the concentration-time curve (AUC) from time zero to the last determined concentration-time point (tf) in the post distribution phase was calculated using the trapezoidal rule. The area under the curve from the last concentration-time point in the post distribution phase (Ctf) to time infinity was calculated from AUC1-∞=Ctf/Kel. The concentration used for Ctf was the last determined value above the LLOQ at the time point. The total AUC0-∞ was obtained by adding AUC1f and AUCt-∞. Noribogaine apparent clearance (CL/F) was determined using the formula CL/F=Dose/AUC0-∞×1000, and apparent volume of distribution (Vd/F) was determined using the formula Vd/F=(CL/F)/Kel. Total urine noribogaine was the sum of both analytes.
- Summary statistics (means, standard deviations, and coefficients of variation) were determined for each dose group for safety laboratory test data, ECG and pharmacokinetic parameters, and pharmacodynamic variables. Categorical variables were analysed using counts and percentages. Dose-proportionality of AUC and Cmax was assessed using linear regression. The effect of dose on pharmacodynamic parameter values over time was assessed using two-factor analysis of variance (ANOVA). Pairwise comparisons (with Tukey-Kramer adjustment) between each dose group to the placebo were conducted at each time point using the least squares estimates obtained from the ANOVA, using SAS Proc Mixed (SAS ver 6.0).
- Pharmacokinetics: Mean plasma concentration-time plots of noribogaine are shown in
FIG. 1 , and mean pharmacokinetic parameters are shown in Table 6. -
TABLE 6 3 mg (n = 6) 10 mg (n = 6) 30 mg (n = 6) 60 mg (n = 6) (mean (SD)) (mean (SD)) (mean (SD)) (mean (SD) Noribogaine AUC0-∞ 74.2 (13.1) 254.5 (78.9) 700.4 (223.3) 1962.2 (726.5) (ng · hr/ml) AUC0-216 72.2 (13.2) 251.4 (78.5) 677.6 (221.1) 1935.4 (725.4) (ng · hr/ml) Cmax 5.2 (1.4) 14.5 (2.1) 55.9 (14.8) 116.0 (22.5) (ng/ml) Tmax (hr) 1.9 (0.6) 2.9 (1.8) 1.8 (0.6) 2.4 (0.6) t1/2 (hr) 40.9 (8.7) 49.2 (11.5) 27.6 (7.0)) 29.1 (9.3) Vd/F (L) 2485.1 (801.5) 3085.8 (1197.0) 1850.8 (707.9) 1416.8 (670.1) CL/F (L/h) 41.4 (7.0) 42.3 (12.0) 46.9 (16.4) 34.0 (11.4) Noribogaine glucuronide AUC0-∞ — — 25.8 (9.3) 67.1 (21.9) (ng · hr/ml) AUC0-216 — — 25.7 (9.1) 65.0 (21.5) (ng · hr/ml) Cmax — — 1.8 (0.6) 4.1 (1.2) (ng/ml) Tmax (hr) — — 3.0 (0.6) 3.8 (1.2) t1/2 (hr) — — 20.6 (4.9) 23.1 (3.0) - Noribogaine was rapidly absorbed, with peak concentrations occurring 2-3 hours after oral dosing. Fluctuations in individual distribution-phase concentration-time profiles may suggest the possibility of enterohepatic recirculation (see highlighted individual 4-8 hour profiles in
FIG. 1 , insert). Both Cmax and AUC increased linearly with dose (Table 6, upper panel). Mean half-life estimates of 28-50 hours were observed across dose groups for noribogaine. Volume of distribution was extensive (1417-3086 L across dose groups). - Mean plasma noribogaine glucuronide concentration-time plots for the 30 mg and 60 mg dose group are shown in
FIG. 2 , and mean pharmacokinetic parameters are shown in Table 6, lower panel. Noribogaine glucuronide was detected in all subjects by 0.75 hours, with peak concentrations occurring 3-4 hours after noribogaine dosing. Mean half-life of 21-23 hours was estimated for plasma noribogaine glucuronide. The proportion of noribogaine glucuronide Cmax and AUC relative to noribogaine was 3-4% for both dose groups. Total urine noribogaine elimination was 1.16 mg and 0.82 mg for the 30 mg and 60 mg dose groups respectively, representing 3.9% and 1.4% of the doses administered. - Pharmacodynamics: There was no evidence of pupillary constriction in subjects dosed with noribogaine. No between-dose group differences in pupil diameter were detected over time. After adjusting for baseline differences, comparison of each dose group with placebo by ANOVA showed no statistically significant differences (p>0.9).
- Noribogaine treatment showed no analgesic effect in the cold pressor test. Analgesic effect was assessed based on duration of hand immersion in ice water and on visual analog scale (VAS) pain scores upon hand removal from the water bath. For duration of hand immersion, after adjusting for baseline differences, comparison of each dose group with placebo by ANOVA showed no statistically significant differences (p>0.9). Similarly, for VAS pain scores, after adjusting for baseline differences, comparison of each dose group with placebo by ANOVA showed no statistically significant differences (p=0.17).
- Safety and tolerability of noribogaine were tested in the group of volunteers from Example 1. Cold pressor testing was conducted in 1° C. water according to the method of Mitchell et al. (J Pain 5:233-237, 2004) pre-dose, 6, 24, 48, 72 and 216 hours post-dosing. Safety evaluations included clinical monitoring, recording of adverse events (AEs), safety laboratory tests, vital signs, ECO telemetry from −2 h to 6 h after dosing, and 12-lead electrocardiograms (ECGs) up to 216 hours post-dosing.
- A total of thirteen adverse events were reported by seven participants (Table 7). Six adverse events were reported by three participants in the placebo group, five adverse events were reported by two subjects in the 3 mg dose group, and one adverse event was reported by single subjects in the 10 mg and 30 mg dose groups, respectively. The most common adverse events were headache (four reports) and epistaxis (two reports). All adverse events were of mild-moderate intensity, and all resolved prior to study completion. There were no changes in vital signs or safety laboratory tests of note. In particular, there were no changes in oximetry or capnography, or changes in respiratory rate. There were no QTcF values>500 msec at any time. One subject closed with 10 mg noribogaine had a single increase in QTcF of >60 msec at 24 hours post-dosing.
-
TABLE 7 Dose (mg) Mild Moderate Severe Placebo Blepharitis Epistaxis — Bruising Dry Skin Eye pain, nonspecific Infection at cannula site 3 Back pain Headache — Dizziness Epistaxis Headache 10 Headache — — 30 Headache — — 60 — — — - The efficacy of noribogaine in humans was evaluated in opioid-dependent participants in a randomized, placebo-controlled, double-blind trial. In the first cohort, six patients were orally administered a single dose of 60 mg noribogaine, and three patients received placebo. In the second cohort, five patients were orally administered a single dose of 120 mg noribogaine, and three patients received placebo. Treatment was administered 2 hours after last morphine dose and the time to resumption of morphine (opioid substitution treatment, OST) was determined. No adverse effects of noribogaine were observed in any of the participants, including no hallucinatory effects.
-
FIG. 3 indicates the serum noribogaine concentration over time. Serum concentrations for 120 mg dose (black squares) are estimated based on data from the 60 mg dose (gray diamonds). - Patients in the first cohort exhibited an average time to resumption of opioids after treatment with 60 mg noribogaine or placebo of approximately 8.7 hours, which is almost 2 hours longer than that reported for untreated patients in a similar study. Patients in the second cohort exhibited an average time to resumption of opioids after treatment with 120 mg noribogaine or placebo of approximately 23 hours.
FIG. 4A indicates the average time to resumption of morphine for control (untreated, light gray bar), first cohort (dark gray bar) and second cohort (black bar). Mean prolongation of the QT interval was less than 10 ms for patients in the first cohort and was less than 40 ms in the second cohort. -
FIG. 4B indicates the estimated noribogaine concentration (based on the data fromFIG. 3 ) at the time of resumption of morphine for each patient. - Although the study was blinded, the patients in the second cohort who received placebo were construed to be those patients exhibiting no prolongation of the QT interval. The average time to resumption of OST for the remaining five patients was determined to be approximately 26.8 hours, as indicated in
FIG. 5A (black bar).FIG. 5B indicates the estimated noribogaine concentration (based on the data fromFIG. 3 ) at the time of resumption of morphine for each (presumed) noribogaine-treated patient.
Claims (24)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/346,655 US20160271139A1 (en) | 2013-03-15 | 2014-03-14 | Method for non-toxic treatment for drug withdrawal |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361852485P | 2013-03-15 | 2013-03-15 | |
US14/346,655 US20160271139A1 (en) | 2013-03-15 | 2014-03-14 | Method for non-toxic treatment for drug withdrawal |
PCT/US2014/028946 WO2014144508A2 (en) | 2013-03-15 | 2014-03-14 | Method for non-toxic treatment for drug withdrawal |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160271139A1 true US20160271139A1 (en) | 2016-09-22 |
Family
ID=51537436
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/346,655 Abandoned US20160271139A1 (en) | 2013-03-15 | 2014-03-14 | Method for non-toxic treatment for drug withdrawal |
US14/214,157 Abandoned US20140288056A1 (en) | 2013-03-15 | 2014-03-14 | Methods for non-toxic treatment for drug withdrawal |
US14/295,273 Active US9744174B2 (en) | 2013-03-15 | 2014-06-03 | Method for noribogaine treatment in patients on methadone |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/214,157 Abandoned US20140288056A1 (en) | 2013-03-15 | 2014-03-14 | Methods for non-toxic treatment for drug withdrawal |
US14/295,273 Active US9744174B2 (en) | 2013-03-15 | 2014-06-03 | Method for noribogaine treatment in patients on methadone |
Country Status (14)
Country | Link |
---|---|
US (3) | US20160271139A1 (en) |
EP (1) | EP2968355A4 (en) |
JP (1) | JP2016514679A (en) |
KR (1) | KR20150130461A (en) |
CN (1) | CN105307658A (en) |
AR (1) | AR095338A1 (en) |
AU (1) | AU2014228986A1 (en) |
BR (1) | BR112015022465A2 (en) |
CA (2) | CA2942638A1 (en) |
EA (1) | EA201591679A1 (en) |
HK (1) | HK1220381A1 (en) |
TW (1) | TW201505634A (en) |
WO (2) | WO2014143201A1 (en) |
ZA (1) | ZA201507514B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077118B2 (en) | 2014-09-12 | 2021-08-03 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
US11197866B2 (en) | 2014-11-26 | 2021-12-14 | Demerx, Inc. | Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2664335C (en) | 2006-09-20 | 2014-12-02 | Boehringer Ingelheim International Gmbh | Rho kinase inhibitors |
WO2014143201A1 (en) | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
US9561232B2 (en) | 2014-02-18 | 2017-02-07 | Demerx, Inc. | Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use |
AU2015219172A1 (en) * | 2014-02-18 | 2016-09-29 | Demerx, Inc. | Therapeutic methods employing noribogaine and related compounds |
KR20160120781A (en) | 2014-02-18 | 2016-10-18 | 데메알엑스, 인크. | Methods for acute and long-term treatment of drug addiction |
US9591978B2 (en) | 2014-03-13 | 2017-03-14 | Demerx, Inc. | Methods and compositions for pre-screening patients for treatment with noribogaine |
US9549935B2 (en) | 2014-07-14 | 2017-01-24 | Demerx, Inc. | Methods and compositions for treating migraines using noribogaine |
WO2016134019A1 (en) * | 2015-02-19 | 2016-08-25 | Demerx, Inc. | Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors |
EP3340984A4 (en) * | 2015-05-11 | 2019-06-19 | DemeRx, Inc. | Methods for treatment of opioid dependency and withdrawal using noribogaine |
KR102579582B1 (en) | 2015-11-17 | 2023-09-15 | 에어리 파마슈티컬즈, 인코포레이티드 | Methods for Preparing Kinase Inhibitors and Intermediates Thereof |
KR102409785B1 (en) | 2017-03-23 | 2022-06-16 | 삼성전자주식회사 | Apparatus and method for performing initial access in wireless communication system |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
KR20220009954A (en) | 2019-04-17 | 2022-01-25 | 컴퍼스 패쓰파인더 리미티드 | Neurocognitive Disorder, How to Treat Chronic Pain and Reduce Inflammation |
GB2600657A (en) * | 2019-07-15 | 2022-05-04 | Demerx Inc | Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2817623A (en) | 1956-03-22 | 1957-12-24 | Ciba Pharm Prod Inc | Tabernanthine, ibogaine containing analgesic compositions |
US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US4806341A (en) | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US5149538A (en) | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
ATE324897T1 (en) * | 1994-07-25 | 2006-06-15 | Nda Int Inc | USE OF NORIBOGAIN DERIVATIVES TO TREAT CHEMICAL DEPENDENCY IN MAMMALS |
US5591738A (en) | 1994-10-14 | 1997-01-07 | Nda International, Inc. | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof |
US5616575A (en) | 1995-12-04 | 1997-04-01 | Regents Of The University Of Minnesota | Bioactive tricyclic ibogaine analogs |
US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
AU754088B2 (en) | 1997-09-04 | 2002-11-07 | Demerx, Inc. | Noribogaine in the treatment of pain and drug addiction |
US6416793B1 (en) | 2000-07-11 | 2002-07-09 | Bioresponse, L.L.C. | Formulations and use of controlled-release indole alkaloids |
US20030153552A1 (en) | 2002-02-14 | 2003-08-14 | Mash Deborah C. | Method of treating chemical dependency in mammals and a composition therefor |
US6939538B2 (en) * | 2002-04-11 | 2005-09-06 | Biomedical Research Models, Inc. | Extended release analgesic for pain control |
US6933308B2 (en) | 2002-12-20 | 2005-08-23 | Bristol-Myers Squibb Company | Aminoalkyl thiazole derivatives as KCNQ modulators |
US20060229293A1 (en) | 2005-04-06 | 2006-10-12 | Addiction Research Institute, Inc. | Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C |
US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
CN103079571A (en) | 2010-07-23 | 2013-05-01 | 德莫科斯公司 | Noribogaine compositions |
WO2012024401A2 (en) | 2010-08-17 | 2012-02-23 | University Of Florida Research Foundation, Inc. | Intelligent drug and/or fluid delivery system to optimizing medical treatment or therapy using pharmacodynamic and/or pharmacokinetic data |
US8648198B2 (en) | 2011-01-19 | 2014-02-11 | Cold Spring Harbor Laboratory | Phenylethanolamine-based NMDA receptor antagonists |
EP2481740B1 (en) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
CN103561746B (en) | 2011-03-18 | 2018-05-29 | 奥克梅斯制药爱尔兰有限公司 | Pharmaceutical composition comprising sorbitan ester |
US8742096B2 (en) | 2011-03-28 | 2014-06-03 | Demerx, Inc. | Methods and compositions for preparing noribogaine from voacangine |
US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
RU2014105881A (en) | 2011-09-15 | 2015-10-20 | Демеркс, Инк. | NORIBOGAIN SALTS ANSOLVATES |
CA3122767C (en) | 2011-12-08 | 2023-03-28 | Demerx, Inc. | Stereoselective total synthesis of noribogaine |
EP2788356A4 (en) | 2011-12-09 | 2015-10-21 | Demerx Inc | Sulfate esters of noribogaine |
CA2855994A1 (en) * | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Phosphate esters of noribogaine |
WO2013112622A1 (en) | 2012-01-25 | 2013-08-01 | Demerx, Inc. | (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof |
US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
WO2013112673A1 (en) | 2012-01-25 | 2013-08-01 | Demerx, Inc. | Synthetic voacangine |
PL2693223T3 (en) | 2012-08-03 | 2022-01-10 | Abb Schweiz Ag | Voltage measurement device with an insulating body |
US8940728B2 (en) | 2012-12-20 | 2015-01-27 | Demerx, Inc. | Substituted noribogaine |
US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
WO2014143201A1 (en) | 2013-03-15 | 2014-09-18 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
US9345711B2 (en) | 2014-02-18 | 2016-05-24 | Demerx, Inc. | Methods for acute and long-term treatment of drug addiction |
US9561232B2 (en) | 2014-02-18 | 2017-02-07 | Demerx, Inc. | Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use |
KR20160120781A (en) | 2014-02-18 | 2016-10-18 | 데메알엑스, 인크. | Methods for acute and long-term treatment of drug addiction |
AU2015219172A1 (en) | 2014-02-18 | 2016-09-29 | Demerx, Inc. | Therapeutic methods employing noribogaine and related compounds |
US20150246055A1 (en) | 2014-03-03 | 2015-09-03 | Demerx, Inc. | Methods for acute and long-term treatment of opioid and opioid-like drug addiction |
US20150258105A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of alcohol dependence |
US20150258108A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods and compositions for reducing tolerance to opioid analgesics |
US20150258111A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods and compositions for reducing tolerance to opioid analgesics using ibogaine and derivatives thereof |
US9591978B2 (en) | 2014-03-13 | 2017-03-14 | Demerx, Inc. | Methods and compositions for pre-screening patients for treatment with noribogaine |
US20150258106A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse |
US9561233B2 (en) | 2014-03-13 | 2017-02-07 | Demerx, Inc. | Use of ibogaine for the treatment of pain |
US20150258114A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods for acute and long-term treatment of substance abuse using ibogaine |
US20150258107A1 (en) | 2014-03-13 | 2015-09-17 | Demerx, Inc. | Methods and compositions for treating depression |
WO2015163844A1 (en) | 2014-04-21 | 2015-10-29 | Demerx, Inc. | N-substituted noribogaine prodrugs |
US20150342959A1 (en) | 2014-06-03 | 2015-12-03 | Demerx, Inc. | Methods and compositions for sustained noribogaine treatment |
CA2989550C (en) | 2014-06-18 | 2023-08-08 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
US9549935B2 (en) | 2014-07-14 | 2017-01-24 | Demerx, Inc. | Methods and compositions for treating migraines using noribogaine |
EP3915639B1 (en) | 2014-11-26 | 2023-06-07 | DemeRx, Inc. | Methods and compostions for potentiating the action of opioid analgesics using iboga alkaloids |
WO2016134019A1 (en) | 2015-02-19 | 2016-08-25 | Demerx, Inc. | Methods for treating disorders associated with undesired activity of neuronal nicotinic acetylcholine receptors |
-
2013
- 2013-11-08 WO PCT/US2013/069235 patent/WO2014143201A1/en active Application Filing
- 2013-11-08 CA CA2942638A patent/CA2942638A1/en active Pending
-
2014
- 2014-03-14 US US14/346,655 patent/US20160271139A1/en not_active Abandoned
- 2014-03-14 AU AU2014228986A patent/AU2014228986A1/en not_active Abandoned
- 2014-03-14 AR ARP140101042A patent/AR095338A1/en unknown
- 2014-03-14 BR BR112015022465A patent/BR112015022465A2/en not_active IP Right Cessation
- 2014-03-14 TW TW103109815A patent/TW201505634A/en unknown
- 2014-03-14 CN CN201480026839.0A patent/CN105307658A/en active Pending
- 2014-03-14 EP EP14764408.2A patent/EP2968355A4/en not_active Withdrawn
- 2014-03-14 KR KR1020157028464A patent/KR20150130461A/en not_active Application Discontinuation
- 2014-03-14 US US14/214,157 patent/US20140288056A1/en not_active Abandoned
- 2014-03-14 CA CA2942511A patent/CA2942511A1/en not_active Abandoned
- 2014-03-14 EA EA201591679A patent/EA201591679A1/en unknown
- 2014-03-14 JP JP2016502943A patent/JP2016514679A/en active Pending
- 2014-03-14 WO PCT/US2014/028946 patent/WO2014144508A2/en active Application Filing
- 2014-06-03 US US14/295,273 patent/US9744174B2/en active Active
-
2015
- 2015-10-09 ZA ZA2015/07514A patent/ZA201507514B/en unknown
-
2016
- 2016-07-19 HK HK16108510.6A patent/HK1220381A1/en unknown
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11077118B2 (en) | 2014-09-12 | 2021-08-03 | Demerx, Inc. | Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake |
US11197866B2 (en) | 2014-11-26 | 2021-12-14 | Demerx, Inc. | Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids |
US11260059B2 (en) | 2014-11-26 | 2022-03-01 | Demerx, Inc. | Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids |
Also Published As
Publication number | Publication date |
---|---|
HK1220381A1 (en) | 2017-05-05 |
EP2968355A2 (en) | 2016-01-20 |
CN105307658A (en) | 2016-02-03 |
EA201591679A1 (en) | 2016-05-31 |
US9744174B2 (en) | 2017-08-29 |
BR112015022465A2 (en) | 2017-07-18 |
WO2014144508A2 (en) | 2014-09-18 |
US20140288056A1 (en) | 2014-09-25 |
AR095338A1 (en) | 2015-10-07 |
EP2968355A4 (en) | 2016-08-24 |
WO2014143201A1 (en) | 2014-09-18 |
TW201505634A (en) | 2015-02-16 |
AU2014228986A1 (en) | 2015-10-29 |
CA2942511A1 (en) | 2014-09-18 |
KR20150130461A (en) | 2015-11-23 |
US20150045350A1 (en) | 2015-02-12 |
CA2942638A1 (en) | 2014-09-18 |
ZA201507514B (en) | 2018-05-30 |
JP2016514679A (en) | 2016-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160271139A1 (en) | Method for non-toxic treatment for drug withdrawal | |
AU638992B2 (en) | A slimming pharmaceutical composition | |
DE69434794T2 (en) | COMBINATION OF DEXTROMETHORPHANE WITH QUINIDINE OR QUININE SULPHATE TO TREAT VARIOUS REFRACTORY INTERFERENCE | |
EP3380095B1 (en) | Compositions and methods for treating ischemic stroke | |
US20150258107A1 (en) | Methods and compositions for treating depression | |
KR20160120781A (en) | Methods for acute and long-term treatment of drug addiction | |
Røikjer et al. | Diabetic peripheral neuropathy: diagnosis and treatment | |
Olagbende-Dada et al. | Blood glucose lowering effect of aqueous extract of Graptophyllum pictum (Linn) Griff. on alloxan-induced diabetic rats and its acute toxicity in mice | |
US9492454B2 (en) | Use of pemirolast in the treatment of acute asthma | |
Aboubakr | Evaluation of bioequivalence of two enrofloxacin formulations after intramuscular administration in goats | |
US20150258112A1 (en) | Methods and compositions for treating depression using ibogaine | |
Hegde et al. | Anti-diabetic potential of ethanolic extract of Holarrhena antidysenterica Linn Leaves | |
US20160038505A1 (en) | Methods and compositions for treating impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake | |
EP3651770B1 (en) | Theacrine-based supplement and method of use thereof in a synergistic combination with caffeine | |
EP3649132B1 (en) | Dual acting kappa and delta opioid agonist for use in treating pain caused by an inflammatory response | |
US20200069675A1 (en) | Pharmaceutical preparations of sebacoyl dinalbuphine and acetaminophen and methods for treating pain | |
WO2022215950A1 (en) | Compound for prevention or treatment of kidney disease | |
Moshi et al. | Some pharmacological properties of an aqueous extract of Securinega virosa roots | |
Sijuade | Effect of methanolic extract of Passiflora foetida on glucose kinetics in alloxan-induced diabetic mice | |
EP4321160A1 (en) | Compound for preventing or treating diabetes | |
RU2794363C1 (en) | Pharmaceutical compositions for treatment of infectious-inflammatory diseases | |
EP3378481A1 (en) | Composition for preventing or treating pancreas fatty infiltration and relieving pancreatic lesions, diabetes or other related symptoms caused by pancreas fatty infiltration, and method | |
Schuh et al. | Pharmacokinetics of a single orally administered therapeutic dosage of cyclosporine A in healthy cats | |
Chae et al. | Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects | |
WO2024010885A1 (en) | Composition for intermittent dosing of calcineurin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PHARMACEUTICAL SPECIAL PROJECTS GROUP, LLC, NEW JE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FRIEDHOFF, LAWRENCE;REEL/FRAME:033449/0674 Effective date: 20140714 Owner name: PHARMACEUTICAL SPECIAL PROJECTS GROUP, LLC, NEW JE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FRIEDHOFF, LAWRENCE;REEL/FRAME:033449/0649 Effective date: 20140714 |
|
AS | Assignment |
Owner name: DEMERX, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMACEUTICAL SPECIAL PROJECTS GROUP LLC;REEL/FRAME:033585/0349 Effective date: 20140714 |
|
AS | Assignment |
Owner name: DEMERX, INC., FLORIDA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PHARMACEUTICAL SPECIAL PROJECTS GROUP, LLC;REEL/FRAME:033595/0343 Effective date: 20140714 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |